Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial disease~* Unsuitable for revascularization~* Minor tissue loss (Rutherford Category 5) or ischemic rest pain (Rutherford Category 4) with ABI ≤ 0.6, or TBI ≤ 0.4, or TcPO2 ≤ 50 mm Hg~* Competent to give consent~* No current malignancy or history of previous malignancy within the last five years, with the exception of adequately treated non-melanoma skin cancer (evidence of standard preventative cancer screenings required)~Exclusion Criteria:~* Major tissue loss (Rutherford Category 6)~* Diabetics on oral or insulin therapy with uncontrolled or untreated proliferative retinopathy (evidence of retinal exam required)~* Poorly controlled diabetes mellitus with HbA1C \> 10% (evidence of HbA1C test required)~* Uncompensated congestive heart failure (New York Heart Association Class IV) and/or other conditions that preclude general anesthesia~* Myocardial infarction or stroke within last 90 days~* Elevated liver function tests (AST or ALT more than twice normal upper limit)~* Renal disease (creatinine \> 2.5 mg/dl) or chronic hemodialysis~* White blood cell count \< 3,000/µL or \> 15,000/µL, platelet count \< 100,000/µL, or hematocrit \< 32%~* Topical growth hormone therapy within last 90 days, or injected growth hormone therapy within last 180 days~* Disease of central nervous system and/or other conditions that impair cognitive function~* Two or more episodes of pulmonary embolus with a documented DVT in index leg or history of DVT in index leg without evidence of clot resolution~* Current infection of index leg~* Pregnant women (negative urine pregnancy test required)~* Lower extremity venous disease with pitting edema in index leg~* Recent history (in the 6 months prior to screening) of bone marrow disease or treatment with any medication or procedure which adversely affects the bone marrow and would prohibit transplantation~* Current osteomyelitis in index leg~* Existing HIV diagnosis~* Organ transplant recipients~* Known terminal disease process with life expectancy less than one year~* Severe concomitant disease(s) or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject~* Major amputation required within 30 days~* Inclusion in any other clinical study that may affect the outcome of this study~* Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac artery and/or common femoral artery of the index leg.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concentrated bone marrow aspirate (cBMA) (Type: EXPERIMENTAL): Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
- Placebo control (sham) (Type: SHAM_COMPARATOR): Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb

Based on this trial design, predict the completion outcome and termination type (if applicable).